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Number of patients 23
Number of lesions treated 43
Number of stents 45
Stent diameter (mm) 2.90.6
Stent length (mm) 17.16.2
Length of follow-up (days) 709348
MI/mortality on follow-up 0
Binary restenosis 5.57% (3/45)
Target vessel revascularization 16.7% (5/30)
Target lesion revascularization 6.98% (3/43)
Quantitative coronary angiography (QCA)
Pre-
procedure
Post-
procedure
Follow-up p-value
RVD (mm) 2.660.79 2.890.75 2.820.71 <0.05
Diameter stenosis (%) 74.915.9 8.083.63 11.16.67 <0.0001
MLD (mm) 0.650.34 2.650.67 2.490.63 <0.0001
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comSS point). The clinical SS was superior to baseline SS in predicting 3-year POCE
(AUC: 0.595 vs. 0.649, p¼0.008). In subgroup analysis, baseline SS was a predictor
for POCE only in multi-vessel diseases (HR 1.027, 95% CI 1.001-1.054, p¼0.042
per SS point).
Conclusions: CR is an independent predictor of 3-year POCE in patients receiving
PCI. However, even after CR is achieved to make the post-PCI SS zero, baseline SS
still has predictive value of 3-year clinical outcomes. Moreover, the predictivity is was
superior in multi-vessel diseases.
TCT-99
Clinical outcome, safety, patient satisfaction and costs savings of same-day
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Background: Overnight admission after elective percutaneous coronary inter-
vention(PCI)still constitutes the standard approach in most interventional cardiology
centers. Advances in PCI techniques have reduced the incidence of post-procedure
complications. The objective of this prospective,single-center study was to assess
the feasibility, safety, acceptance and cost savings of same-day discharge PCI
program.
Methods: Eligibility for outpatient management was assessed in 95 consecutive
patients undergoing elective PCI from January 2013 to April 2014. Exclusion
criteria for early discharge were age>80, severe renal failure, LVEF< 35%,
distance from home to hospital >40 km, high risk coronary anatomy or com-
plications during procedure. Major adverse cardiac events,vascular complications
and readmission were assessed 1-day and 1-month post discharge. Troponin,
EKG and a satisfaction survey were collected within 24 hours post PCI sched-
uled visit.
Results: 39 patients (41%) were cleared for discharge. The remaining 56(59%)
stayed overnight for high risk coronary anatomy (n¼51, 91%), chest discomfort
(n¼4, 7%) or treatment with abciximab (n¼1, 2%). Mean post PCI hospital stay
was 8:48 h for outpatients group. None patient was readmitted. There were no
vascular complications. EKG collected in 24-hours-visit show non-speciﬁc changes
in 3 patients. 7 patients hd troponin elevation without angina or EKG ischemic
changes. After one-month follow up only 2 patients had adverse events: a bare
metal stent thrombosis (day 7 after procedure) and 1 gastrointestinal bleeding with
diagnosis of colonic cancer. These complications could not have been avoided with
overnight hospital admission. Early discharge was well valuated with mean patient
satisfaction score of 4,50,5 (1 to 5). 87% of outpatients would choose early
discharge in case of new PCI. Using diagnosis-related groups costs established
in our institution, there were lower cost in the early discharge group, with a mean
cost of 2.480 vs 2.880 Euro in the routine care group. Mean of expense savings
was 16%.
Conclusions: In our experience same-day discharge after elective PCI is feasible, safe
and well accepted in selected patients and results in a cost-saving strategy.
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Background: Transplant coronary artery disease (TCAD) is a major cause of mor-
tality in patients after orthotopic heart transplantation (OHT). Use of systemic ever-
olimus has been shown to help prevent allograft vasculopathy in OHT patients. This
study examined the clinical and angiographic efﬁcacy, safety, and clinical outcomes of
Xience V, a second-generation everolimus-eluting stent (EES), in patients with
TCAD.
Methods: Post-OHT patients with hemodynamically signiﬁcant CAD (left main
50% or angiographic diameter stenosis 70%) underwent percutaneous coronary
intervention (PCI) with EES. We examined procedural success rates, one- and two-
year mortality, and myocardial infarction rates. Primary end-point was target lesion
revascularization (TLR). Surveillance angiography was performed at 1 year and
subsequently as clinically indicated on a per-patient basis. Quantitative coronary
angiography (QCA) was used for stenosis analysis at baseline, post-procedure, and
follow-up.
Results: 23 patients were included in the study. PCI was performed in 43 lesions
with 45 denovo EES placed. 2 stents were placed into the left main, 20 in the left
anterior descending, 12 in the right coronary, and 9 in the left circumﬂex artery. The
average stent length was 17.16.2mm and the average stent diameter was
2.90.6mm. Procedural success rate was 100%. All patients received angiographic
follow-up, with average length of follow-up 709348 days. There were no peri-
procedural, 1-year, or 2-year deaths/ MIs. Binary restenosis events were 5.57%
(3/45). Target vessel revascularization (TVR) rate was 16.7% (5/30), and TLR rate
was 6.98% (3/43).B30 JACC Vol 64/11/Suppl B j SeptembConclusions: Long term follow-up of EES placements in OHT patients with TCAD
are associated with a very low incidence of target lesion revascularization. Continued
follow-up and further studies are indicated to determine whether EES can positively
affect the progression and overall outcome of TCAD.
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Background: Routine control angiography is a valuable tool with high-sensitivity in
detecting restenosis after coronary stenting. However, the prognostic role of restenosis
is still controversial. We investigated the impact of restenosis on 4-year mortality in
patients undergoing routine control angiography after coronary stenting.
Methods: All patients undergoing successful implantation of coronary stents for de
novo lesions from 1998 to 2009 and routine control angiography after 6 to 8 months at
2 centres in Munich, Germany were studied. Restenosis was deﬁned as diameter
stenosis50% in the in-segment area at follow-up angiography. The primary outcome
was 4-year mortality.
Results: This study included 10,004 patients with 15,004 treated lesions. Restenosis
was detected in 2,643 (26.4%) patients. Overall, there were 702 deaths during
follow-up. Of these, 218 deaths occurred among patients with restenosis and 484
deaths occurred among patients without restenosis (unadjusted hazard ratio - HR
1.19; [95% conﬁdence interval - CI 1.02 to 1.40]; p¼ 0.03). The Cox proportional
hazards model adjusting for other variables identiﬁed restenosis as an independent
correlate of 4-year mortality (HR 1.23; [95% CI 1.03 to 1.46]; p¼ 0.02). Other
independent correlates of 4-year mortality were age (for each 10-year increase, HR
2.34; [95% CI 2.12 to 2.60]; p< 0.001), diabetes mellitus (HR 1.68; [95% CI 1.41 to
1.99]; p< 0.001), current smoking habit (HR 1.39; [95% CI 1.09 to 1.76]; p¼ 0.01)
and left ventricular ejection fraction (for each 5% decrease, HR 1.39; [95% CI 1.31
to 1.48]; p< 0.001).
Conclusions: In this large cohort of patients with routine control angiography after
coronary stenting the presence of restenosis was a strong independent predictor of
4-year mortality.
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Background: Chest pain and angina have negative impact on patient quality of life
and medical costs. Real-world data describing the incidence of recurrent angina, chest
pain and their impact on re-intervention following percutaneous coronary intervention
(PCI) are scarce. We sought to describe the incidence and impact of post-PCI angina
and chest pain using real-world data from a large claims database.er 13–17, 2014 j TCT Abstracts/Angioplasty Overview and Outcomes
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMMethods: We used claims data from the Truven Health MarketScan Commercial and
Medicare Supplemental Databases to identify adults with incident PCI (index event)
from 2008-2011. We excluded patients who had less than 12 months of continuous
medical and pharmacy beneﬁts before or after the index procedure; patients were
followed for 12 - 24 months after their index PCI. Baseline characteristics were
deﬁned in the 12-month pre-index period. Clinical outcomes were deﬁned as an
inpatient claim with a principal diagnosis of angina, chest pain, or acute coronary
syndrome (ACS); new angina or chest pain were also deﬁned by presence of an
outpatient claim with an accompanying stress test or repeat PCI. Repeat PCI was
deﬁned as a PCI occurring at least 30 days post-index; PCIs < 30 days post-index
were considered staged procedures.
Results: A total of 51,710 patients met the study criteria (mean age 61.8
[SD¼11.3], 72.4% male). Of these, 33,197 (64.2%) had 24 months of follow-up.
Cumulative incidence of post-index angina or chest pain was 24.8% in the ﬁrst year
and increased to 33.9% by end of year 2. At two years, 4.1% of patients had had an
ACS event. Repeat PCI occurred in 10.8% of patients by one year and 15.1% by
two years.
Conclusions: Persistent or recurrent angina and chest pain remains a signiﬁcant
clinical challenge. Recurrent events, including angina, chest pain, and repeat-PCI,
occurred in approximately one-quarter of patients in the ﬁrst year post-procedure
and increased in the second year of post-procedure follow-up, indicating substantial
burden to patients and payers. Strategies that reduce these adverse events are
needed.
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Background: Previous studies have shown gender impact on clinical outcomes in
patients presenting with coronary artery disease. However, exact role of gender impact
in these studies still have not been fully investigated.
Methods: Gender differences were evaluated in the clinical outcomes of 9,674
patients with coronary artery disease from a large, 55 multicenter, contemporary
percutaneous coronary intervention (PCI) registry enrolled between April 2008
and November 2011 in Korea; the IRIS DES registry. 3,097 women and 6,577
men were followed-up for more than 2 year. The primary end point was rates of
major adverse cardiovascular events (MACE), deﬁned as cardiac death,
myocardial infarction (MI), and target vessel revascularization (TVR) at 2 year
follow-up.
Results: At baseline, women, as compared with men, were older, more frequently had
diabetes, hypertension, and previous congestive heart failure, less frequently had
smoking habits, family history of coronary artery disease, previous MI, and previous
PCI, and had a smaller average stent diameter of the target vessel. The unadjusted
rates of death (3.5% vs 3.3%, P¼0.578), MACE (6.0% vs 6.0%, p¼0.946), and TVR
(1.8% vs1.6%, p¼0.573) were comparable for women and men. MI (1.1% vs 0.9%,
p¼0.494) were similar between men and women. After adjustment for baseline
characteristics in the multivariable analysis, women and men had a similar risk of
MACE rates at 2 year follow up.
Conclusions: Although women had worse baseline characteristics, no differences
in MACE and death were observed between men and women undergoing PCI
with DES.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AngioplasTCT-104
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Background: Although direct stenting with drug-eluting stents (DES) has been
adopted as standard of care, its safety and effectiveness in comparison to the formally
recommended conventional pre-dilatation strategy remains not well established.
Methods: Medline/Pubmed, Cochrane Library, and EMBASE were searched from
2001 to 2014 for studies contrasting Direct DES with conventional pre-dilatation DES
implantation. The primary outcome was major adverse cardiovascular events
(MACE). Secondary outcomes included all-cause death or myocardial infarction (MI),
and target lesion revascularization (TLR). Summarized estimates were obtained using
a random-effects model. Heterogeneity across the studies was assessed through I2.
Results: Overall, 546 potentially relevant citations were screened with 407 excluded
from the title. The remaining 139 abstracts were analyzed resulting in six studies that
met the inclusion criteria enrolling a total of 10,513 participants. Of those, 3909 (37%)
and 6604 (63%) underwent direct DES or pre-dilatation followed by DES implanta-
tion, respectively. Direct DES reduced the likelihood of MACE (odds ratio [OR]: 0.80
95% conﬁdence interval [CI]: 0.70-0.92) with no evidence of heterogeneity of effect
(I2¼ 0%). Additionally, in comparison with pre-dilatation, Direct DES was also
associated with reduced rates of death or MI (OR: 0.74 95% CI [0.60-0.91], I2¼ 0%),
and TLR (OR: 0.60 95% CI [0.41-0.88],I2¼ 14%)(Figure).
Conclusions: Our ﬁndings support the strategy of direct DES for selected patient and
lesion population.TCT-105
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Coronary Stent System
Shigeru Saito1, William C. Wijns2
1Shonan Kamakura General Hospital, Kanagawa, Japan, 2Cardiovascular Center
Aalst, Aalst, Belgium
Background: In an effort to harmonize regulatory approval in Japan and Europe we
conducted large, multicentre, randomized CENTURY II clinical trial to assess per-
formance of new sirolimus-eluting stent with bioresorbable polymer (Ultimas-
ter,Terumo Corporation, Tokyo) fully designed and manufactured in Japan. We
compared Ultimaster with Xience DES. The study also addressed regional differences
in percutaneous intervention practice.
Methods: The CENTURY II enrolled 1123 patients in 58 hospitals in Europe, Japan
and Korea. The randomization was stratiﬁed for DES indications in Japan and in this
cohort 724 patients were enrolled. The principal difference from the total population
was exclusion of patients with acute myocardial infarction, left main disease, 3 vessels
disease, ostial lesion, saphenous vein graft, and in-stent restenosis. Primary endpointty Overview and Outcomes B31
